“Genome Editing Global Market – Forecast To 2022”

IQ4I Research & Consultancy Pvt. Ltd. Page 1

Genome Editing Global Market

–Forecast to 2022

Genome Editing Global Market estimated to be worth $2.6 billion by 2022 IQ4I Research & Consultancy published a new report on “Genome Editing Global

Market – Forecast To 2022” This report analyzes and studies the overall market, major

drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and

Rest of the World

IQ4I’s Report Contains 68 market data tables and 45 figures spread through 274 pages

and an exhaustive TOC on “Genome Editing Global Market [TECHNOLOGY (ZFN,

TALEN, CRISPR and Others), APPLICATION (basic research, agriculture/plant

biotechnology, animal biotechnology and drug discovery & development),

PRODUCTS AND SERVICES (reagents, enzymes and consumables, cell lines and

animal models, genome editing services, instruments and software), END USERS

(academic and government institutions, plant biotechnology companies,

pharmaceutical and biotechnology companies and others (animal biotechnology and

contract research organizations (CRO)), REGION (North America, Europe, Asia-Pacific

and Rest of the World)]

This report analyzes the Genome editing global market in terms of market revenue ($

million) for all segments and it enables genome editing stakeholders such as academic and

government institutions, plant biotechnology, pharmaceutical, biotechnology, animal

biotechnology companies and contract research organizations (CRO) to identify and analyze

market expansion opportunities, upcoming technologies and competition in genome editing

global market.

Gene editing broadly refers to a suite of methods that use programmable endonuclease to

target a specific site in the genome that can induce double stranded break (DSB) which are

then repaired by disrupting or modifying the target sequence. There are four major classes

of gene editing technologies, including meganuclease and their derivatives, Zinc Finger

Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Clustered

Regularly Interspaced Short Palindromic (CRISPR)-associated nuclease Cas9. These

nucleases can be broadly divided into two classes based on their mode of DNA recognition;

ZFN, TALEN and meganucleases bind to DNA via protein-DNA interaction, whereas Cas9

binds to DNA with a short guide RNA (g RNA) by Watson-Crick base-pairing. Moreover,

transposons are used as gene editing tools that can integrate desired genes into the host

genome by using their inherent ‘cut and paste’ process. As per IQ4I estimates, the overall

genome-editing market is expected to reach $2,669.9 million by 2022.



–Forecast to 2022

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries,

increasing private and public sector funding, rapid advancements in sequencing and gene

editing technologies, non-labeling of gene edited products as Genetically Modified

Organisms (GMOs), applications in various drug discovery processes and are some of the

factors driving the genome editing global market growth. Factors such as stringent regulatory

framework, ethical issues concerning editing human embryo and adverse public perception,

unavailability of gene-editing based therapeutics in market, off-target effects of CRISPR and

patent disputes associated with CRISPR technology are hampering the market growth.

The global genome editing market, based on technology type is segmented into ZFN,

TALEN, CRISPR and Others. CRISPR held the largest market share of and is expected to

grow at a high double digit CAGR from 2015 to 2022.

Based on application genome editing market is classified into basic research,

agriculture/plant biotechnology, animal biotechnology and drug discovery & development.

Basic research accounted for largest share of and is expected to grow at a high CAGR from

2015 to 2022. Drug discovery and development is further segmented into pre-clincal and

clinical.

The global genome market by products and services is segmented into reagents, enzymes

and consumables, cell lines and animal models, genome editing services, instruments and

software. Reagents, enzymes and consumables accounted for largest share and is

expected to grow at double digit CAGR from 2015 to 2022.

Genome editing end users market is segmented into academic and government institutions,

Plant biotechnology companies, pharmaceutical and biotechnology companies and others

that include animal biotechnology and contract research organizations (CRO). Academic and

government institutes accounted for largest share of is expected to grow at double digit

CAGR from 2015 to 2022.

Some of the major companies in the genome editing market are Applied Stemcell (U.S.),

Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA

(Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences

(U.S.), Thermo Fisher Scientific (U,S,) and Transposagen BioPharmaceuticals (U.S.).Other

companies include GE Healthcare (U.K.), Agilent Technologies (U.S.) New England Biolabs

(NEB) (U.S.), Integrated DNA Technologies (IDT) (U.S.), Lonza (Switzerland), Addgene

(U.S.), Precision Biosciences (U.S.), Bluebird Bio (U.S.), Editas Medicine (U.S.), Caribou



–Forecast to 2022

Bioscience (U.S.), CRISPR Therapeutics (Switzerland), ERS Genomics (Ireland) and Takara

Bio (Japan).

Reasons for buying this report:

Analysis of the Genome Editing global market by identifying various segments by

type, end-users and geography.

Revenue forecast of the Genome Editing market and strategic analysis of each

submarket with respect to segmental growth trends.

Analysis of the major market trends and factors driving or inhibiting the growth of the

Genome Editing global market.

Revenue forecast of the Genome Editing market with respect to North America,

Europe, Asia-Pacific and the Rest of the World (RoW) regions.

Analysis of the opportunities for stakeholders by identifying the high-growth

segments of the market.

Market share analysis of key players in genome editing, details of their product

offerings, revenues, business strategies and SWOTs

Established and Emerging players (63 companies) and their product offerings.



–Forecast to 2022

FIGURE 1

GENOME EDITING GLOBAL MARKET SEGMENTATION


By Technology By Applications By Products

ZFN

TALEN

CRISPR

Basic Research

Agriculture/Plant biotechnology

Animal Biotechnology

Reagents, Enzymes & Consumables

Instruments

Cell lines & Animal models

Academic & Government Institutes

Pharmaceutical & Biotechnology

Plant biotechnology

Others

By End-Users

OthersDrug Discovery and

developmentSoftware & Genome

editing services